COVID-19 vaccines were not associated with increased risk for thyroid diseases but were associated with increased risk for exacerbated hypothyroidism.

Hence, researchers recommended that people who received it get a second booster dose with an mRNA vaccine such as Moderna and Pfizer. According to the published results, there were 129 coronavirus ...

Moderna now projects $1.5 billion to 2.5 billion in revenue in 2025, mostly in the second half of the year ... with no events meeting protocol-defined dose-limiting toxicity criteria.

Moderna now projects $1.5 billion to 2.5 billion in revenue in 2025, mostly in the second half of the year ... well-tolerated to date with no events meeting protocol-defined dose-limiting toxicity ...

There's one big difference though - Pfizer is seeking a green light for second booster dose of Comirnaty for people aged 60 and over and those in high-risk groups, while Moderna is going for a ...

Moderna is down 80% from its 52-week high as ... and try to beat 2025 revenue guidance. The second regulatory catalyst is a potential expanded label for mRESVIA in high-risk adults 18-59 years ...

Moderna says it has ... s jab or Sanofi’s high-dose flu vaccine Fluzone HD, co-administered with Moderna’s currently licensed COVID-19 jab Spikevax. A second group of adults aged 50 to 64 ...

H5N1 vaccines have been previously licensed, and millions are in the national stockpile. But even with the news of the ...